Russia Cancer Vaccine: The Federal Medical-Biological Agency (FMBA) of Russia has announced the successful completion of preclinical trials for its cancer vaccine, demonstrating both safety and high efficacy. The announcement was made by FMBA head Veronika Skvortsova during the Eastern Economic Forum (EEF). Initially developed to target colorectal cancer, the vaccine showed a significant reduction in tumor size and improved survival rates in clinical trials.
Further research is also underway to develop vaccines for glioblastoma and melanoma. The 10th Eastern Economic Forum was held in Vladivostok on September 3-6 under the theme “The Far East: Cooperation for Peace and Prosperity.”
Russia’s Cancer Vaccine ‘Ready For Use’
According to Skvortsova, the research spanned several years, with the last three dedicated to mandatory preclinical studies. She added that the vaccine is now ready for use, and the agency is just waiting for the official approval. Skvortsova highlighted that preclinical results confirmed the vaccine’s safety, even with repeated administration, and its significant effectiveness.
The Researchers observed reductions in tumour size and slowed tumour progression, ranging from 60% to 80%, depending on the disease characteristics. Additionally, studies indicated increased survival rates attributable to the vaccine. The initial target for this vaccine will be colorectal cancer.
A good progress has been also made in developing vaccines for glioblastoma and specific types of melanoma, including ocular melanoma, which is currently at advanced stages of development. Notably, Cancer vaccines are currently available for some prostate and bladder cancers, and more are being researched, as per the American Cancer Society.
Also Read: Japan PM Shigeru Ishiba Resigns After Coalition Loses Upper House Majority
